A Study of LY900014 in Participants With Type 1 Diabetes

• Status: Completed
• Trial end date: 2019-08-22
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin; Insulin Glargine; Insulin Lispro; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Have T1D for at least 1 year prior to screening and continuously using insulin for at least 1 year.

• HbA1c of ≥7.0 and ≤9.5%.

• Use insulin lispro, insulin aspart, or insulin glulisine as prandial insulin.

• Use insulin glargine, insulin detemir, insulin degludec, or neutral protamine Hagedorn (NPH) insulin as basal insulin.

Exclusion Criteria:

• Have used other antihyperglycemic medications or therapies (inhaled, oral or injectable) within 90-days of screening.

• Have had more than 1 severe hypoglycemic episode within 6 months of screening.

• Have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis within 6 months of screening.

• Have clinically significant gastrointestinal disease.